CTOs on the Move

Connect Hearing

www.connecthearing.com

 
We provide a strong network of convenient neighborhood hearing care centers across the country that continually strives to find innovative ways to serve you better. Our Hearing Care Professionals are passionate about helping people to hear better, applying a consistent process to determine the best recommendations for your hearing health. We provide free next day evaluations with professional recommendations based upon your inidiviudal hearing needs and lifestyle. We offer a walk-in, walk-out 2-week FREE trial with hearing aids that are right for you - plus the Connect Advantage, your assurance Connect Hearing will be there every step of the way. Headquartered in the Chicago ...
  • Number of Employees: 0-25
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Sven Davies
Vice President of Information Technology Profile

Similar Companies

Mountain Laurel Medical Center

Mountain Laurel Medical Center is a community health center that provides primary health care, wellness promotion, and education to individuals in Garrett County and surrounding areas.

Sempre Health

Sempre Health is bringing behavior-based, individualized copays to healthcare. Today, we work with health plans and pharma manufacturers to dynamically adjust copays based on individual adherence and behavior, seamlessly at the point of fill.

Cyntellect

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology.

Cape Medical Supply

Cape Medical Supply is a Sandwich, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.